Jeffrey S. Farrow - 16 Jun 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Financial Officer and Chief Strategy Officer
Signature
/s/ Jeffrey Farrow
Issuer symbol
TARS
Transactions as of
16 Jun 2025
Net transactions value
-$550,035
Form type
4
Filing time
18 Jun 2025, 16:07:59 UTC
Previous filing
20 Mar 2025
Next filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Farrow Jeffrey S Chief Financial Officer and Chief Strategy Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Jeffrey Farrow 18 Jun 2025 0001405253

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +27,881 +124% 50,312 16 Jun 2025 Direct F1
transaction TARS Common Stock Sale $550,035 -13,608 -27% $40.42 36,704 17 Jun 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -27,881 -33% $0.000000 55,763 16 Jun 2025 Common Stock 27,881 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F4 RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

Remarks:

Chief Financial Officer and Chief Strategy Officer